Articles

A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase III trials of ruxolitinib for the treatment of myelofibrosis

University of Florence, Italy
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Hôpital Saint-Louis et Université Paris Diderot, Paris, France
Stanford Cancer Institute, CA, USA
Hospital Clínic, Institut d’Investigacions Biomèdiques August Pi i Sunyer, Barcelona, Spain
Mayo Clinic, Scottsdale, AZ, USA
Incyte Corporation, Wilmington, DE, USA
Incyte Corporation, Wilmington, DE, USA
Incyte Corporation, Wilmington, DE, USA
Novartis Pharma AG, Basel, Switzerland
Novartis Pharma AG, Basel, Switzerland
Novartis Pharma AG, Basel, Switzerland
Princess Margaret Cancer Center, University of Toronto, Ontario, Canada
Guy’s and St. Thomas’ NHS Foundation Trust, Guy’s Hospital, London, UK
The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Vol. 100 No. 9 (2015): September, 2015 https://doi.org/10.3324/haematol.2014.119545